Are These The Top Health Care Stocks To Watch This Week?
While investors look for up-and-coming stocks in the stock market now, health care stocks continue to shine. After all, this sector of the market is home to countless companies looking to improve our overall quality of life. Whether it is vaccine companies such as Pfizer (NYSE: PFE) or retail pharmacy chains like Walgreens (NASDAQ: WBA) this is apparent. Because of all this, it would not surprise me to see investors looking out for the best health care stocks.
If anything, the health care industry today is constantly researching and innovating on all fronts. For instance, biotech company AC Immune (NASDAQ: ACIU) is making waves in the stock market today on account of its latest update. Namely, the company reported positive results in clinical trials of its Alzheimer’s treatment, semorinemab. It is reportedly well tolerated with an acceptable safety profile and no unanticipated safety signals. By and large, the health care industry remains a vital and ever-evolving one right now. Should all this have you keen on the top health care stocks in the market now, here are five to watch.
Best Health Care Stocks To Watch Ahead Of September 2021
- General Electric Company (NYSE: GE)
- Regional Health Properties (NYSE: RHE)
- RedHill Biopharma Ltd. (NASDAQ: RDHL)
- Moderna Inc. (NASDAQ: MRNA)
- Pacific Biosciences of California Inc. (NASDAQ: PACB)
General Electric Company
General Electric is a multinational conglomerate with headquarters in New York. The company actually has a health care segment that focuses on global medical technology, digital solutions innovation, and pharmaceutical diagnostics. Also, the company has helped clinicians and health care providers make faster and more informed decisions through its medical devices, data analytics, and applications. Notably, GE stock currently trades at $105.41 as of Tuesday’s closing bell and has more than doubled in valuation in the past year.
Earlier in the month, the company announced a strategic collaboration agreement with Amazon (NASDAQ: AMZN) Web Services to deliver artificial intelligence and cloud-based imaging solutions. The two companies will also provide integrated data and clinical insights to hospitals and health care providers.
This would ultimately help health care providers transition from the traditional care delivery model provided in the hospital setting to a more decentralized model that is virtual and distributed. This would be in line with an overwhelming majority of physicians that say access to the right data at the right time will help them improve care. Given this piece of news, will you be watching GE stock?
Regional Health Properties Inc.
Next up on this list, we have Regional Health Properties. For the uninitiated, the company is a self-managed health care real estate investment company that invests primarily in real estate purposed for senior living and long-term health care through facility lease and sub-lease transactions. It currently owns, leases, or manages for third parties, 30 facilities. RHE stock closed Tuesday’s trading session up 34.66% and currently trades at $11.19 a share.
The company recently reported its second-quarter financials on August 16, 2021. It ended the quarter with $5.6 million of unrestricted cash and has secured refinancing commitments on $3.6 million of debt with a previously scheduled maturity in the third quarter of 2022.
Ben Waites, Regional’s Chief Financial Officer had this to say, “Both the equity and debt capital structure improvements that we are pursuing should allow the Company to move into a growth mode and take advantage of opportunities presented by the COVID-19 disruption.” With that being said, do you think RHE stock is worth buying right now?
RedHill Biopharma Ltd
RedHill is a specialty biopharmaceutical company that focuses on gastrointestinal and infectious diseases. Its gastrointestinal drug is Movantik, for opioid-induced constipation in adults. It has a pipeline that includes several drug candidates in advanced clinical development stages and has commercial operations in North Carolina. RDHL stock currently trades at $10.10 as of Tuesday’s closing bell and is up by over 17% on today’s trading day.
Investors seem to be responding to the company after it announced its second-quarter financials on Thursday. Firstly, it posted a record quarterly revenue of $21.5 million, up by 4.5% from the previous quarter. It also saw a record Talicia quarterly prescription volume that was up by more than 10%, while its Movantik prescriptions were up by 5.6%.
Its COVID-19 treatment, opaganib, which is used to treat patients with severe COVID-19 has shown promising results from its preclinical data. For these reasons, will you consider adding RDHL stock into your portfolio of health care stocks?
Following that, we have the coronavirus vaccine frontrunner Moderna. As most would know, the company exploded onto the scene last year thanks to its work researching the coronavirus. Through its vaccine, the company has and continues to inoculate hundreds of millions of people globally against the current pandemic. Because of all this, MRNA stock could be a viable bet on the health care industry for many investors now.
As it stands, MRNA stock closed Tuesday’s trading session at $376.69. Notably, this would be after gaining by over 230% year-to-date. Even with its current momentum, Moderna continues to gain traction thanks to its industry-leading work.
According to a study published by the American Medical Association, Moderna’s vaccine reportedly produces more than twice the antibodies when compared to the Pfizer-BioNTech vaccine. Additionally, the company also recently completed the submission for full FDA approval of its coronavirus vaccine last week. Could this make MRNA stock worth adding to your watchlist now?
Pacific Biosciences of California Inc.
Pacific Biosciences of California (PacBio) is a biotech company that develops and manufactures systems for gene sequencing and novel real-time biological observations. By combining the many advances of biotechnology, the company has created a powerful technology platform called the single-molecule, real-time (SMRT) technology. In essence, this enables real-time analysis of biomolecules with single-molecule resolution. PACB stock currently trades at $31.31 as of Tuesday’s closing bell and is up by over 350% in the past year.
On the operational front, the company does not seem to be slowing as well. Earlier this month, PacBio acquired Circulomics, a leading provider of high-quality, long-read sequencing platforms. Safe to say, this move would synergize well with the rest of PacBio’s portfolio. CEO Christian Henry explained, “By adding the team to PacBio we will be able to deeply integrate their technology into our workflows which will improve our entire long-read sequencing workflow.” All things considered, will you be keeping an eye on PACB stock now?